Dr. Nazma Ilahibaks is CEO and co-founder of JAMA Tx, solving one of the hardest problem in genetic medicine for heart patients — delivery. JAMA Tx is developing a new platform enabling multimodality delivery of RNA, protein, and programmable gene editors into heart tissue for treating cardiogenetic diseases. As platform co-inventor, she has secured over €1.3M in competitive funding to drive preclinical validation with a dedicated team. In earlier business development roles, she closed 20 contracts worth over €2.0M with leading pharma and medtech partners within 12 months, and managed a €6.3M R&D portfolio in interventional cardiology. Additionally, she supported the creation of new cardiovascular and regenerative medicine ventures from academia in the Netherlands through the DCVA/RegMed XB Thematic Technology Transfer program. She has 8+ years of experience developing non-viral delivery systems for cardiovascular disease applications and holds a PhD in Regenerative Medicine from Utrecht University.